Request Demo

Last update 08 May 2025

Concord Medical Services (International) Pte Ltd.

Subsidiary Company|Singapore

Last update 08 May 2025

Overview

Pipeline

Deal

Translational Medicine

Overview

100 Clinical Results associated with Concord Medical Services (International) Pte Ltd.

0 Patents (Medical) associated with Concord Medical Services (International) Pte Ltd.

Literatures (Medical) associated with Concord Medical Services (International) Pte Ltd.

15 Sep 2017·Oncotarget

Molecular characterization of circulating colorectal tumor cells defines genetic signatures for individualized cancer care

Article

Author: Ying, Jackie Y. ; Tai, Joyce A. ; Tan, Min-Han ; Hillmer, Axel M. ; Koh, Poh Koon ; Kong, Say Li ; Phyo, Wai Min ; Foong, Yu Miin ; Suhaimi, Nur-Afidah Mohamed ; Lee, Esther Xing Wei ; Lim, Bing ; Koh, Kenneth Jia Hao ; Vo, Jess Honganh ; Zhang, Tong ; Cima, Igor ; Lee, Daniel Yoke San ; Hu, Min ; Liu, Xingliang

Studies on circulating tumor cells (CTCs) have largely focused on platform development and CTC enumeration rather than on the genomic characterization of CTCs. To address this, we performed targeted sequencing of CTCs of colorectal cancer patients and compared the mutations with the matched primary tumors. We collected preoperative blood and matched primary tumor samples from 48 colorectal cancer patients. CTCs were isolated using a label-free microfiltration device on a silicon microsieve. Upon whole genome amplification, we performed amplicon-based targeted sequencing on a panel of 39 druggable and frequently mutated genes on both CTCs and fresh-frozen tumor samples. We developed an analysis pipeline to minimize false-positive detection of somatic mutations in amplified DNA. In 60% of the CTC-enriched blood samples, we detected primary tumor matching mutations. We found a significant positive correlation between the allele frequencies of somatic mutations detected in CTCs and abnormal CEA serum level. Strikingly, we found driver mutations and amplifications in cancer and druggable genes such as APC, KRAS, TP53, ERBB3, FBXW7 and ERBB2. In addition, we found that CTCs carried mutation signatures that resembled the signatures of their primary tumors. Cumulatively, our study defined genetic signatures and somatic mutation frequency of colorectal CTCs. The identification of druggable mutations in CTCs of preoperative colorectal cancer patients could lead to more timely and focused therapeutic interventions.

01 Sep 2017·Molecular Cancer TherapeuticsQ2 · MEDICINE

Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patient–Derived Xenografts

Q2 · MEDICINE

Article

Author: Foo, Roger Sik Yin ; Mohamed Suhaimi, Nur-Afidah ; Choy, Sharon Heng Yee ; Tiang, Zenia ; Choudhury, Yukti ; Phyo, Wai Min ; Tan, Wai Jin ; Tan, Min-Han ; Koh, Poh Koon ; Tan, Suzanne Hui San ; Wei, Xiaona ; Yap, Hao Yun ; Wong, Chin Fong ; Tan, Luke Anthony Peng Yee

AbstractThere is increasing preclinical evidence suggesting that metformin, an antidiabetic drug, has anticancer properties against various malignancies, including colorectal cancer. However, the majority of evidence, which was derived from cancer cell lines and xenografts, was likely to overestimate the benefit of metformin because these models are inadequate and require supraphysiologic levels of metformin. Here, we generated patient-derived xenograft (PDX) lines from 2 colorectal cancer patients to assess the properties of metformin and 5-fluorouracil (5-FU), the first-line drug treatment for colorectal cancer. Metformin (150 mg/kg) as a single agent inhibits the growth of both PDX tumors by at least 50% (P < 0.05) when administered orally for 24 days. In one of the PDX models, metformin given concurrently with 5-FU (25 mg/kg) leads to an 85% (P = 0.054) growth inhibition. Ex vivo culture of organoids generated from PDX demonstrates that metformin inhibits growth by executing metabolic changes to decrease oxygen consumption and activating AMPK-mediated pathways. In addition, we also performed genetic characterizations of serial PDX samples with corresponding parental tissues from patients using next-generation sequencing (NGS). Our pilot NGS study demonstrates that PDX represents a useful platform for analysis in cancer research because it demonstrates high fidelity with parental tumor. Furthermore, NGS analysis of PDX may be useful to determine genetic identifiers of drug response. This is the first preclinical study using PDX and PDX-derived organoids to investigate the efficacy of metformin in colorectal cancer. Mol Cancer Ther; 16(9); 2035–44. ©2017 AACR.

29 Jun 2016·Science Translational MedicineQ1 · MEDICINE

Tumor-derived circulating endothelial cell clusters in colorectal cancer

Q1 · MEDICINE

Article

Author: van Dam, Rob M. ; Koh, Poh Koon ; Robson, Paul ; Chew, Min Hoe ; Iliescu, Ciprian ; Lim, Wei-Yen ; Ten, Rachel ; Cima, Igor ; Kong, Say Li ; Ying, Jackie Y. ; Rahmani, Mehran ; Hu, Min ; Phyo, Wai Min ; Tan, Min-Han ; Tai, Joyce A. ; Lim, Wan Jun ; Tan, Joanna H. ; Prabhakar, Shyam ; Alexander, Irina ; Hillmer, Axel M. ; Goh, Wei Lin ; Suhaimi, Nur-Afidah Mohamed ; Tan, Iain B. ; Chua, Clarinda ; Sengupta, Debarka ; Lim, Bing ; Lee, Daniel ; Hauser, Charlotte A. E. ; Vo, Jess H.

A population of cell clusters circulating in cancer patients consist of tumor-derived endothelial cells reflecting features of the tumor vasculature.

100 Deals associated with Concord Medical Services (International) Pte Ltd.

100 Translational Medicine associated with Concord Medical Services (International) Pte Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 10 Dec 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Concord Medical Services (International) Pte Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 10 Dec 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing